MDMA and Green Tea Extract (EGCG): Help or Harm?

Not medical advice. This article is for harm reduction and educational purposes only. Nothing here is a recommendation to use any substance. If you are experiencing a medical emergency, call your local emergency services immediately. Some links may be affiliate links — we earn a small commission at no cost to you.

Green tea extract (EGCG) appears in some MDMA supplement protocol guides alongside alpha-lipoic acid and magnesium, cited for its antioxidant and neuroprotective properties. The pharmacology here is more complicated than most protocol guides suggest, and the common framing — that EGCG is dangerous because it causes serotonin syndrome — is only partially accurate. The stronger concern is different: EGCG inhibits an enzyme involved in MDMA’s metabolism, which creates unpredictable potentiation rather than serotonin toxicity. And the evidence that EGCG protects against MDMA neurotoxicity is weaker than it’s often presented. The bottom line: leave it out of the stack.

Quick answers

Is green tea extract safe to take with MDMA? Not recommended. EGCG inhibits MAO-B, an enzyme involved in MDMA metabolism, which can potentiate MDMA’s effects unpredictably. The neuroprotection evidence is preclinical and indirect.

Does EGCG cause serotonin syndrome with MDMA? MAO-B inhibition alone is generally not sufficient to cause serotonin syndrome — MAO-A is the isoform primarily responsible for serotonin breakdown. The potentiation risk is more relevant than the serotonin syndrome risk.

Why does EGCG appear in MDMA supplement protocols? Because MDMA causes oxidative stress and EGCG is an antioxidant. The theoretical basis exists, but no human study and no direct MDMA + EGCG study in animals has verified the neuroprotective benefit at realistic doses.

Should I take green tea extract before or after MDMA? Neither. The evidence for benefit is insufficient and the interaction with MDMA metabolism is not well-characterized at supplement doses. See the MDMA supplement protocol for evidence-ranked alternatives.

What EGCG is and why it shows up in MDMA protocols

Epigallocatechin gallate (EGCG) is the primary polyphenol in green tea, comprising roughly 50–80% of the catechin content in green tea extract supplements. It is one of the most studied dietary antioxidants.

The logic for including it in an MDMA supplement protocol: MDMA produces neurotoxicity in animals via oxidative stress, and EGCG is a potent antioxidant. Several antioxidants — alpha-lipoic acid, Vitamin C, NAC — have demonstrated neuroprotective effects against MDMA-induced oxidative damage in rat models. EGCG, being a more powerful antioxidant by some measures, was added to community protocols by extension.

The problem is that “EGCG is an antioxidant” and “antioxidants reduce MDMA neurotoxicity in rats” does not follow to “EGCG reduces MDMA neurotoxicity.” The specific molecule matters, and EGCG has not been tested directly alongside MDMA in the way ALA has.

The neuroprotection evidence: what it actually shows

The closest available preclinical evidence is a 2020 mouse study (PMID 32080803) showing that EGCG pretreatment protected against striatal dopamine terminal toxicity caused by methamphetamine, not MDMA. The protection was attributed to antioxidant mechanisms reducing oxidative damage. This is relevant because MDMA and methamphetamine share some neurotoxicity pathways, but they are not the same drug, and the finding does not transfer directly.

More importantly: the methamphetamine dose in that study was 30 mg/kg injected intraperitoneally in mice. Using the FDA body surface area conversion for mouse-to-human scaling, the human equivalent dose for a 75 kg person is roughly 180 mg of methamphetamine — a toxic dose, not a recreational one. These are neurotoxicity-induction models designed to damage animal brains in a controlled way. Whether EGCG provides any meaningful protection at the concentrations achievable through supplement doses in a recreational MDMA context is unknown.

No direct study combining EGCG with MDMA in animals or humans exists with verified publication. The neuroprotection case for EGCG in MDMA protocols is built on indirect inference, not evidence.

The MAO-B inhibition: a more complicated story

EGCG inhibits monoamine oxidase B (MAO-B), the enzyme that primarily breaks down dopamine (PMID 20472400, PMID 22887993). This is where the pharmacology gets interesting.

MAO-B also plays a role in MDMA’s metabolism. In rat models, selective MAO-B inhibitors — including L-deprenyl (selegiline), the Parkinson’s drug — significantly attenuated MDMA-induced serotonin depletion and lipid peroxidation (PMID 7538579, PMID 7542394). The reason: MAO-B converts certain MDMA metabolites (alpha-methyldopamine) into reactive quinones that damage serotonergic terminals. Blocking MAO-B reduces that toxic metabolic pathway.

This creates a pharmacological paradox. Inhibiting MAO-B might reduce MDMA’s neurotoxic metabolite formation. But MAO-B also breaks down dopamine under normal circumstances. When you inhibit it, dopamine accumulates in the synapse — and MDMA is already releasing massive amounts of dopamine. The result is stronger, more prolonged dopaminergic effects. How much potentiation this produces at the concentrations delivered by a green tea extract supplement is not established.

The practical consequence: EGCG may make MDMA feel stronger and last longer in ways that are not predictable or dose-controllable. This is a real concern regardless of the serotonin syndrome question.

The serotonin syndrome question: what the evidence actually says

Many protocol guides categorize EGCG + MDMA as high-risk due to serotonin syndrome. The mechanism cited: EGCG inhibits MAO-B → less serotonin breakdown → excess serotonin → serotonin syndrome.

This framing overstates the risk. Serotonin syndrome requires excess activation of serotonin receptors, typically through multiple simultaneous mechanisms (PMID 24358002). MAO-B is not the primary enzyme responsible for serotonin metabolism — MAO-A is. A 2007 study demonstrated directly that MAO-A inhibition (not MAO-B) is the enzymatic mechanism that drives serotonin syndrome risk (PMID 17721552).

Clinical data supports this. A systematic review of patients taking selegiline (a selective MAO-B inhibitor used in Parkinson’s disease) combined with SSRIs found a serotonin syndrome rate of only 0.24% — and selegiline’s risk may be partially attributable to its amphetamine-like metabolites rather than MAO-B inhibition itself (PMID 29955193). Rasagiline, a cleaner MAO-B inhibitor without those metabolites, showed zero serotonin syndrome cases in a 1,504-patient cohort.

The point is not that EGCG + MDMA is safe — it is not recommended — but that the specific mechanism behind the concern is dopaminergic potentiation, not serotonin syndrome. The distinction matters for understanding what to watch for. The warning signs of dangerous MDMA potentiation (overheating, cardiovascular strain, prolonged overstimulation) are different from the classic serotonin syndrome triad (clonus, rigidity, hyperthermia with muscle signs).

What this means for the supplement protocol

The MDMA supplement protocol is based on evidence for specific mechanisms: alpha-lipoic acid for antioxidant/metal chelation, Vitamin C for hydroxyl radical scavenging, magnesium for bruxism and potentially neurotoxicity reduction. Each of those has a cleaner mechanism and no meaningful interaction with MDMA’s metabolic pathway.

EGCG has:

No direct MDMA + EGCG neuroprotection study
A confirmed MAO-B inhibitory effect that creates pharmacological unpredictability
A theoretical (not demonstrated) risk of MAO-A inhibition at higher concentrations
Unclear dose-response for either benefit or interaction at supplement-level doses

The harm reduction calculus is straightforward: when the benefit is uncertain and preclinical, and the interaction adds pharmacological complexity, the rational choice is to omit it. This is not because EGCG is categorically dangerous with MDMA — the serotonin syndrome concern is overstated — but because you are adding uncertainty without demonstrated benefit.

If you have already been taking green tea extract regularly and are concerned about stopping before an MDMA session, a cup of green tea contains roughly 50–100 mg of EGCG. Most green tea extract supplements contain 400–800 mg. The interaction concern scales with dose. A single cup of green tea the day before is a different pharmacological exposure than an 800 mg EGCG supplement taken the same day.

The bottom line

EGCG is not in the evidence-supported MDMA supplement protocol for good reason. The neuroprotection argument depends on indirect inference from a methamphetamine study at toxic doses. The MAO-B inhibitory effect creates real but poorly characterized potentiation. The serotonin syndrome concern, while real, is less pharmacologically grounded than often stated — MAO-A, not MAO-B, is the isoform responsible for serotonin syndrome risk.

For a full breakdown of which supplements have actual evidence, see the MDMA supplement protocol guide. For information on MDMA drug interactions more broadly, see the interaction checker and our MDMA harm reduction guide.